Membrane Receptor and Antiangiogenic Targeted Therapies in the Treatment of Cancer

Author(s): Antonio Jimeno, Hernán Cortes-Funes.

Journal Name: Current Cancer Therapy Reviews

Volume 1 , Issue 1 , 2005

Become EABM
Become Reviewer


The rapidly expanding knowledge of the pathogenesis of a variety of forms of cancer at the molecular level is now providing new targets for drug discovery and development. This has enabled us to successfully develop rationally designed therapies for cancer patients, and the results of their clinical evaluation are now becoming available. The optimal clinical development of target-based anticancer drugs will require fundamental changes to the way trials are designed, outcome is evaluated, and patients are selected to receive therapy. A thorough knowledge of what is accomplished so far is the cornerstone to optimally develop and implement these new strategies.

Keywords: targeted therapy, egfr, her2, vegfr

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [51 - 61]
Pages: 11
DOI: 10.2174/1573394052952519

Article Metrics

PDF: 9